Related Experiment Video
Updated: Nov 21, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors
Hyung Chul Ryu1, Marc Windisch2, Jee Woong Lim1
1R&D Center, J2H Biotech, Suwon, Gyeonggi-do, Republic of Korea.
Abstract:
To develop unique small-molecule inhibitors of hepatitis C virus (HCV), thiophen urea (TU) derivatives were synthesised and screened for HCV entry inhibitory activities. Among them, seven TU compounds exhibited portent anti-viral activities against genotypes 1/2 (EC50 < 30 nM) and subsequently, they were further investigated; based on the pharmacological, metabolic, pharmacokinetic, and safety profiles, J2H-1701 was selected as the optimised lead compound as an HCV entry inhibitor. J2H-1701 possesses effective multi-genotypic antiviral activity. The docking results suggested the potential interaction of J2H-1701 with the HCV E2 glycoprotein. These results suggest that J2H-1701 can be a potential candidate drug for the development of HCV entry inhibitors.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Thiazide-Class Diuretics
Hepatic Drug Excretion: Influencing Factors
Dipeptidyl Peptidase 4 Inhibitors
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Drug Elimination by Renal Route: Tubular Secretion

